Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 37-43

  Guastalla, J P ^a   Pujade Lauraine, E ^b   Weber, B ^b   Cure H ^b   Orfeuvre, H ^b   Mousseau, M ^b   Vincent, P ^b   Dieras V ^b   Tubiana Mathieu, N ^b   Jacquin, J P ^b   Mignot, L ^b   Leduc, B ^b   Viens, P ^b   Pariso, D ^b  

^a CENTRE LÉON BÉRARD   (France)

^b NONE

Author keywords

Carboplatin; Chemotherapy; Ovarian carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RETREATMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0242319868     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008211909585     Document Type: Article

References (31)

1. Anonymous. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group (see comments). BMJ 1991; 303 (6807): 884-93.
2. Neijt JP, Ten Bokkel Huinink WW, Van der Burg ME et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27 (11): 1367-72.
3. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 11: 1273-9.
4. Einzig AI, Wiernik PH, Sasloff J et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
5. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinumbased chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12 (9): 1748-53.
6. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 8: 618-24.
7. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12 (12): 2654-66.
8. McGuire WP, Hoskins WJ, Brady MF et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group study Semin Oncol 1997; 24 (Suppl 2): 13-6.
9. Ten Bokkel Huinink W, Veenhof C, Huizing M et al. Carboplatin and paclitaxel in patients with advanced ovarian cancer: A dose-finding study. Semin Oncol 1997; 24 (Suppl 2): 31-3.
10. Ozols RF. Carboplatin and paclitaxel in ovarian cancer. Semin Oncol 1995; 2: 278-83.
11. Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between Carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10 (4): 520-8.
12. Guastalla JP, Lhomme C, Dauplat J et al. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: An interim analysis of a phase II multicenter study. Ann Oncol 1994; 5 (Suppl 6): 33-8.
13. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 (11): 1748-56.
14. Lhomme C, Guastalla JP, Dauplat J et al. A phase II study of Taxol® (T) (paclitaxel) over 3 hours (H) in 192 platinum pretreated patients (PTS) for ovarian carcinoma (OC). Eur J Cancer 1995; 31A (Suppl 5): 108.
15. Carmichael J, Gordon A, Malfetano J et al. Topotecan, a new-active drug, vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group trial. ASCO 1996; 15 (765): 283
16. du Bois A, Luck HJ, Bauknecht T et al. Phase I/II study of the combination of Carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer (in process citation). Ann Oncol 1997; 8: 355-61.
17. Kjorstad K, Harris A, Bertelsen K et al. A multicenter phase II study of Carboplatin in advanced ovarian carcinoma: Final report. Ann Oncol 1992; 3 (3): 217-22.
18. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994: 55: S143-50.
19. Seltzer V, Vogl S Kaplan B. Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 1985; 21 (2): 167-76.
20. Van der Burg ME, Bon GG, Ooosterom Ret al. Evaluation of the tumor serum markers ca 125. ca 15.3 and ca m29 in monitoring ovarian cancer (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1991; 10: A607.
21. Markman M, Rothman R, Hakes T et al. Late effects of cisplatinbased chemotherapy on renal function in patients with ovarian carcinoma. Gynecol Oncol 1991; 41 (3): 217-9.
22. Blackledge G, Lawton F, Redman C Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59 (4): 650-3.
23. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11 (12): 2405-10.
24. Muggia FM, Braly PS, Brady MF et al. Phase III of cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group (GOG) study. ASCO Proc 1997; (16): 352A.
25. Calvert AH, Boddy A, Bailey NP et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22: 91-8; discussion 99-100.
26. Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol 1995; 221-6.
27. Kearns CM and Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/Carboplatin chemotherapy. Semin Oncol 1997; 24 (Suppl 2): 91-6.
28. Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; (16): 31-41.
29. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87 (8): 573-80.
30. Barth A, Köchli OR, Küng F et al. Comparison of bedside estimates of GFR for AUC dosing of carboplatin in patients with ovarian cancer. Proc Am Soc Clin Oncol 1996; (15): 292.
31. Neijt JP, Hansen M, Sorensen PGet al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. ASCO Proc 1997; (16): 352a.